Covid-19 e risposta immune

1. Giacomet V, Stracuzzi M, Rubinacci V, Zuccotti GV. SARS-CoV-2: quali implicazioni nella popolazione pediatrica. Medico e Bambino 2020;39(2):93-7. 2. Marchetti F. La lezione del coronavirus. Medico e Bambino 2020;39(2):75-7. 3. Guiducci C, Marchetti F. Covid-19 e bambini: il punto dalla letteratura al 18 marzo. Medico e Bambino 2020;39(3):151-3. 4. Sheikh K, Watkins D, Wu J, Gröndahl M. How bad will the coronavirus outbreak get? Here are 6 key factors. New York Times, updated Feb. 28, 2020. 5. Notarangelo LD, Tommasini A. Defective and excessive immunities in pediatric diseases. Curr Pharm Des 2012;18(35): 5729-34. 6. Sieni E, Cetica, V, Aricò, M. Linfoistiocitosi emofagocitica: una sfida diagnostica per il pediatra. Medico e Bambinio 2012; 31(1):21-9. 7. Zunica F, Settini F, Biondi, A, Badolato R. Manifestazioni dell’infezione da virus di Epstein-Barr nel paziente con immunodeficit. Medico e Bambinio 2019;38(3):163-9. 8. Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. Int Immunol 2018;30(5):195-203. 9. Lachmann G, Knaak C, Vorderwulbecke G, et al. Hyperferritinemia in critically ill patients. Crit Care Med Dec 24 [Epub ahead of print]. 10. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020 Mar 12 [Epub ahead of print]. 11. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020 Mar 16 [Epub ahead of print]. 12. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361(9369):1615-7. 13. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168(12): 1449-56. 14. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59(5):414-20. 15. Kan FK, Tan CC, von Bahr Greenwood T, et al. Dengue infection complicated by hemophagocytic lymphohistiocytosis: Experiences from 180 severe dengue patients. Clin Infect Dis 2019;25(2):290-8. 16. McElroy AK, Shrivastava-Ranjan P, Harmon JR, et al. Macrophage activation marker soluble CD163 associated with fatal and severe Ebola virus disease in humans. Emerg Infect Dis 2019;25(2):290-8. 17. Schulert GS, Zhang M, Fall N, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis 2016;213(7):1180-8. 18. Lalueza A, Trujillo H, Laureiro J, et al. Impact of severe hematological abnormalities in the outcome of hospitalized patients with influenza virus infection. Eur J Clin Microbiol Infect Dis 2017;36(10):1827-37. 19. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009 - April 2010). Clin Infect Dis 2011; 52(Suppl 1):S75-82. 20. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426(6965):450-4. 21. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7). 22. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 Mar 4 [Epub ahead of print]. 23. Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 2005;79(12):7819-26. 24. Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 2005;106(7):2366-74. 25. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020 Feb 24 [Epub ahead of print]. 26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 Mar 3 [Epub ahead of print]. 27. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202(3):415-24. 28. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182(2): 383-90. 29. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020 Mar 11 [Epub ahead of print]. 30. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22(11):1041-50. 31. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009;8(1):18-30. 32. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015;282(1821):20143085. 33. Mold JE, McCune JM. Immunological tolerance during fetal development: from mouse to man. Adv Immunol 2012;115:73-111. 34. Thome JJ, Bickham KL, Ohmura Y, et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med 2016;22(1):72-7. 35. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020 Mar 23 [Epub ahead of print]. 36. Cadena AM, Flynn JL, Fortune SM. The importance of first impressions: early events in Mycobacterium tuberculosis infection influence outcome. mBio 2016;7(2):e00342-16. 37. Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016;19(2):181-93. 38. Johnson PL, Goronzy JJ, Antia R. A population biological approach to understanding the maintenance and loss of the T-cell repertoire during aging. Immunology 2014;142(2): 167-75. 39. Mold JE, Reu P, Olin A, et al. Cell generation dynamics underlying naive T-cell homeostasis in adult humans. PLoS Biol 2019; 17(10):e3000383. 40. Gupta M, Jardeleza MS, Kim I, Durand ML, Kim L, Lobo AM. Varicella zoster virus necrotizing retinitis in two patients with idiopathic CD4 lymphocytopenia. Ocul Immunol Inflamm 2016;24(5):544-8. 41. Hochauf K, Bandt D, Pohlmann C, Monecke S, Toma M, Trautmann S. Fatal varicella zoster virus infection as first manifestation of idiopathic CD4+ T-cell lymphocytopenia. Eur J Clin Microbiol Infect Dis 2005;24 (10):706-8. 42. McBath A, Stafford R, Antony SJ. Idiopathic CD4 lymphopenia associated with neuroinvasive West Nile disease: case report and review of the literature. J Infect Public Health 2014;7(2):170-3. 43. Ye P, Kirschner DE. Reevaluation of T cell receptor excision circles as a measure of human recent thymic emigrants. J Immunol 2002;168(10):4968-79. 44. Junge S, Kloeckener-Gruissem B, Zufferey R, et al. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol 2007;37(11):3270-80. 45. Pinti M, Nasi M, Lugli E, et al. T cell homeostasis in centenarians: from the thymus to the periphery. Curr Pharm Des 2010;16 (6):597-603. 46. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497-506. 47. Hayflick L. The future of ageing. Nature 2000;408(6809):267-9. 48. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013;9(10):e1003657. 49. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438(7068):575-6. 50. Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310(5748):676-9. 51. Mohd HA, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir. Virol J 2016;13:87. 52. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RC. The proximal origin of SARS-CoV-2. Nature Medicine 2020 Mar 17 [Epub ahead of print]. 53. Pavlovich SS, Lovett SP, Koroleva G, et al. The Egyptian rousette genome reveals unexpected features of bat antiviral immunity. Cell 2018;173(5):1098-110 e18. 54. Xie J, Li Y, Shen X, et al. Dampened STING-dependent interferon activation in bats. Cell Host Microbe 2018;23(3):297-301 e4. 55. Ahn M, Anderson DE, Zhang Q, et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat Microbiol 2019;4(5): 789-99. 56. Banerjee A, Rapin N, Bollinger T, Misra V. Lack of inflammatory gene expression in bats: a unique role for a transcription repressor. Sci Rep 2017;7(1):2232. 57. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019;10:50. 58. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res 2014;59(1-3):118-28. 59. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020 Mar 18 [Epub ahead of print]. 60. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-71. 61. Xu X; Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 5 marzo 2020. http:// www.chinaxiv.org/abs/202003.00026. 62. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5):529-39. 63. Ritchie AI, Singanayagam, A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet 395(10230):1111.